STANKOVICH THOMAS 4
4 · ReShape Lifesciences Inc. · Filed Mar 7, 2023
Insider Transaction Report
Form 4
STANKOVICH THOMAS
Chief Financial Officer
Transactions
- Sale
Common Stock, $0.001 par value per share
2023-01-24$7.49/sh−48$360→ 6,461 total - Sale
Common Stock, $0.001 par value per share
2023-01-24$7.49/sh−110$824→ 6,351 total - Sale
Common Stock, $0.001 par value per share
2023-02-02$13.29/sh−157$2,087→ 6,194 total - Sale
Common Stock, $0.001 par value per share
2023-02-28$4.25/sh−103$438→ 6,091 total
Footnotes (2)
- [F1]On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
- [F2]On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock.